Profile data is unavailable for this security.
About the company
Arcellx Inc. is a clinical-stage biotechnology company reimagining cell therapy by engineering immunotherapies for patients with cancer and other incurable diseases. Its lead program is a BCMA-targeting ddCAR product candidate called anitocabtagene autoleucel, which is being evaluated in its pivotal Phase II iMMagine-1 and the Phase III iMMagine-3 trials in patients with relapsed or refractory multiple myeloma (rrMM). Anitocabtagene is the first BCMA-directed CAR T-cell therapy to be investigated in multiple myeloma that utilizes its novel and compact binder known as the D-Domain. The small, stable D-Domain binder enables high CAR expression without tonic signaling and is designed to quickly release from the BCMA target. It is also developing two clinical-stage ARC-SparX programs in Phase I trials: ACLX-001, which targets BCMA in rrMM, and ACLX-002, which targets CD123 in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS).
- Revenue in USD (TTM)35.90m
- Net income in USD-217.90m
- Incorporated2014
- Employees163.00
- LocationArcellx Inc800 Bridge ParkwayREDWOOD CITY 94065United StatesUSA
- Phone+1 (240) 327-0603
- Fax+1 (302) 655-5049
- Websitehttps://www.arcellx.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alumis Inc | 22.12m | -245.15m | 3.40bn | 233.00 | -- | 7.14 | -- | 153.83 | -3.85 | -3.85 | 0.3057 | 3.69 | 0.0491 | -- | 9.28 | 131,672.60 | -54.44 | -- | -61.16 | -- | -- | -- | -1,108.24 | -- | -- | -- | 0.00 | -- | -- | -- | -89.84 | -- | -- | -- |
| Grail Inc | 141.83m | -406.24m | 3.67bn | 1.00k | -- | 1.52 | -- | 25.85 | -11.63 | -11.63 | 4.06 | 61.94 | 0.0496 | -- | 9.01 | 141,827.00 | -14.21 | -49.71 | -14.65 | -50.85 | 46.88 | 39.69 | -286.43 | -3,510.18 | -- | -- | 0.00 | -- | 34.90 | -- | -38.30 | -- | 9.34 | -- |
| Erasca Inc | 0.00 | -127.69m | 3.68bn | 103.00 | -- | 9.69 | -- | -- | -0.4506 | -0.4506 | 0.00 | 1.23 | 0.00 | -- | -- | 0.00 | -26.90 | -41.53 | -28.68 | -44.78 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -29.28 | -- | -36.84 | -- |
| Terns Pharmaceuticals Inc | 0.00 | -94.44m | 3.75bn | 59.00 | -- | 10.89 | -- | -- | -1.03 | -1.03 | 0.00 | 3.25 | 0.00 | -- | -- | 0.00 | -27.78 | -32.69 | -28.92 | -35.03 | -- | -- | -- | -33,013.70 | -- | -- | 0.00 | -- | -- | -- | 1.50 | -- | -45.82 | -- |
| Arcellx Inc | 35.90m | -217.90m | 3.87bn | 163.00 | -- | 8.77 | -- | 107.82 | -3.92 | -3.92 | 0.6462 | 7.63 | 0.0505 | -- | 9.57 | 220,233.10 | -30.67 | -27.24 | -37.39 | -32.13 | -- | -- | -607.01 | -212.50 | -- | -- | 0.00 | -- | -2.16 | -- | -51.86 | -- | 28.52 | -- |
| BillionToOne Inc | -100.00bn | -100.00bn | 3.90bn | -- | -- | -- | -- | -- | -- | -- | -- | 4.02 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 5.75 | -- | 0.238 | -- | 112.72 | -- | 49.72 | -- | -- | -- |
| Gyroscope Therapeutics Holdings Ltd(ADR) | -100.00bn | -100.00bn | 3.93bn | 167.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -70.87 | -- | -58.56 | -- | -- | -- |
| CG Oncology Inc | 2.17m | -151.48m | 3.97bn | 113.00 | -- | 5.60 | -- | 1,825.56 | -2.03 | -2.03 | 0.0292 | 8.78 | 0.0034 | -- | 6.67 | 19,238.94 | -23.63 | -- | -24.51 | -- | 4.09 | -- | -6,967.99 | -- | 22.74 | -- | 0.0043 | -- | 458.33 | -- | -29.85 | -- | -- | -- |
| ACADIA Pharmaceuticals Inc | 1.05bn | 261.17m | 3.97bn | 653.00 | 15.11 | 4.33 | 14.42 | 3.79 | 1.55 | 1.55 | 6.21 | 5.42 | 0.9075 | 1.88 | 9.78 | 1,603,550.00 | 22.64 | -13.15 | 32.50 | -16.74 | 91.92 | 94.49 | 24.94 | -16.00 | 2.94 | -- | 0.00 | -- | 31.85 | 23.08 | 469.50 | -- | -14.26 | -- |
| Apogee Therapeutics Inc | 0.00 | -253.67m | 4.24bn | 196.00 | -- | 6.29 | -- | -- | -4.36 | -4.36 | 0.00 | 9.89 | 0.00 | -- | -- | 0.00 | -36.18 | -- | -37.98 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -116.88 | -- | -- | -- |
| Crinetics Pharmaceuticals Inc | 1.54m | -423.10m | 4.25bn | 437.00 | -- | 3.95 | -- | 2,768.86 | -4.53 | -4.53 | 0.0165 | 11.34 | 0.0014 | -- | 0.2622 | 3,512.59 | -39.66 | -36.96 | -42.19 | -39.20 | -- | -- | -27,563.32 | -7,785.98 | -- | -- | 0.00 | -- | -74.11 | -2.73 | -39.10 | -- | 50.86 | -- |
| Amicus Therapeutics, Inc. | 598.70m | -14.06m | 4.48bn | 499.00 | -- | 19.12 | -- | 7.49 | -0.0458 | -0.0458 | 1.94 | 0.7469 | 0.7234 | 0.4175 | 5.65 | 1,199,808.00 | -1.70 | -23.63 | -2.17 | -28.66 | 89.77 | 89.34 | -2.35 | -53.29 | 2.09 | 0.8067 | 0.6298 | -- | 32.29 | 23.72 | 62.99 | -- | -29.23 | -- |
| Scholar Rock Holding Corp | 0.00 | -353.43m | 4.53bn | 196.00 | -- | 17.99 | -- | -- | -3.15 | -3.15 | 0.00 | 2.47 | 0.00 | -- | -- | 0.00 | -119.63 | -45.06 | -144.40 | -51.62 | -- | -- | -- | -1,134.62 | -- | -- | 0.2891 | -- | -- | -- | -48.56 | -- | -49.93 | -- |
| Holder | Shares | % Held |
|---|---|---|
| T. Rowe Price Investment Management, Inc.as of 30 Nov 2025 | 9.60m | 16.61% |
| Fidelity Management & Research Co. LLCas of 30 Sep 2025 | 5.41m | 9.36% |
| Paradigm BioCapital Advisors LPas of 30 Sep 2025 | 4.65m | 8.04% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 3.73m | 6.45% |
| RA Capital Management LPas of 30 Sep 2025 | 3.04m | 5.25% |
| BlackRock Fund Advisorsas of 30 Sep 2025 | 2.72m | 4.71% |
| Perceptive Advisors LLCas of 30 Sep 2025 | 2.47m | 4.27% |
| SSgA Funds Management, Inc.as of 30 Sep 2025 | 1.53m | 2.64% |
| Vestal Point Capital LPas of 30 Sep 2025 | 1.25m | 2.16% |
| T. Rowe Price Associates, Inc. (IM)as of 30 Sep 2025 | 1.23m | 2.13% |
